Title : In vitro study of glycyrrhizic acid-based drug delivery system for allergen-specific immunotherapy
Abstract:
The most effective method of treating allergic diseases is allergen-specific immunotherapy (SIT). To reduce the risk of side effects and improve delivery of allergens to the mucosa, various delivery systems such as liposomes, dendrimers, nanoparticles, etc. can be used. Today, there is a lot of data about delivery systems based on glycyrrhizic acid (GA) and its derivatives, but this delivery systems have not yet been used for allergen-specific therapy. At the same time, it is known that GA has an anti-inflammatory effect, it can shift the balance towards Th1, increase the number of Treg cells, which means that in the future it is able to enhance the anti-allergic effect of SIT and reduce the risk of side effects.
We have studied in our work the effect of the GA supramolecular complex and the allergen of house dust mite Der p 1 on the viability, subpopulation composition and cytokine-producing ability of mononuclear cells of patients with sensitization and doctor-diagnosed allergy to house dust mite allergen and healthy donors. It was found that the complex of GA and Der p1 increased the number of Treg cells in PBMCs compared to free Der p 1. Also, GA-Der p1 complex affect the inflammatory and Th2 cytokine production.
The results of evaluating the effect of the GA complex with Der p 1 on the phenotypic and functional characteristics of PBMCs of PBMCs indicate a change in the Th1/Th2 balance towards the cellular immune response, which can increase the efficiency of the Der p1 peptide during ASIT.
